Related Experiment Video
Updated: Dec 9, 2025

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models
Published on: September 27, 2024
Using Extended Release Buprenorphine Injection to Discontinue Sublingual Buprenorphine: A Case Series
Alexis D Ritvo1, Susan L Calcaterra, Jonathan I Ritvo
1Department of Psychiatry, University of Colorado School of Medicine, Aurora, CO (AR, JR); Division of General Internal Medicine, University of Colorado School of Medicine, Aurora, CO (SLC).
Abstract:
Buprenorphine is highly effective for the treatment of opioid use disorder and is increasingly being used in the treatment of chronic pain. For various reasons, patients on buprenorphine may request discontinuation of this medication. Tapering off buprenorphine can be challenging due to intolerable withdrawal symptoms, including nausea, malaise, anxiety, and dysphoria. A single dose of extended-release buprenorphine may facilitate discontinuation of buprenorphine by mitigating prolonged, debilitating opioid withdrawal symptoms. We report on three cases of successful transition from low dose sublingual buprenorphine to a single injection of 100 mg extended-release buprenorphine to opioid cessation in patients who had previously been unable to taper fully off buprenorphine. This novel use of extended-release buprenorphine provides a viable alternative to fully transition patients off buprenorphine when they are medically and emotionally ready.
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Depolarizing Blockers: Pharmocokinetics
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Desensitization and Tachyphylaxis
Drug Delivery: Enteral Route

